SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has signed an exclusive agreement with CyberKnife Korea (CKK) for the sale and distribution of BSDs hyperthermia products in South Korea. CKK is a premier distributor of sophisticated medical devices in South Korea and represents a number of major medical device companies. CKK is a leading distributor of oncology products in South Korea and has established strong relationships with radiation oncologists throughout the country. As part of the agreement, CKK is required to purchase a minimum number of hyperthermia systems from BSD each year. BSD will initially focus on the regulatory approval for and distribution of the BSD-500 Hyperthermia System and then expand distribution to include the BSD-2000 Hyperthermia System.

South Korea ranks as one of the worlds leading economies, with a population of 61 million and overall GDP among the top 15 in the world. As a result, much of the population expects a high level of medical care. The South Korea medical equipment market is focused on high-end, innovative technology with a strong reliance on imported products. The 2010 oncology market in South Korea was approximately US $840 million.

"We are excited to establish a business relationship with one of the leading oncology product distributors in Korea," stated Harold R. Wolcott, President of BSD Medical. "The Asia Pacific countries are becoming increasingly important as a market and could represent up to 40% of the global health care market by 2015. The receipt of the HDE marketing approval for the BSD-2000 will expand the market in Asia for BSDs hyperthermia products. BSD is committed to establishing strong partnerships in the Asia Pacific countries that will result in increased product sales in this region."

About the BSD Hyperthermia Systems

The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors. The BSD-2000 Hyperthermia System – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 recently received Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSDs product lines include both hyperthermia and ablation treatment systems. BSDs hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSDs microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Companys products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at

Posted by Sean Fenske, Editor-in-Chief, MDT